Detalhe da pesquisa
1.
Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients.
Int J Cancer
; 132(2): E74-84, 2013 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22948846
2.
Syntheses and antitumor activities of N'1,N'3-dialkyl-N'1,N'3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol.
Bioorg Med Chem Lett
; 23(18): 5070-6, 2013 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23937981
3.
UHPLC-MS/MS method to determine FP-208 in human plasma and its application to a pharmacokinetic study.
Bioanalysis
; 12(6): 367-378, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32285686
4.
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
Exp Hematol
; 36(10): 1266-77, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18657349
5.
Elesclomol induces cancer cell apoptosis through oxidative stress.
Mol Cancer Ther
; 7(8): 2319-27, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18723479
6.
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Mol Cancer Ther
; 11(2): 475-84, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22144665